Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.

Jia Li Low,Kenneth Sooi,Yiqing Huang,Gloria Hj Chan,Yvonne L.E. Ang,Wan Qin Chong,Hon-Lyn Tan,Natalie Ngoi,Joan Choo,Matilda Lee,Vaishnavi Muthu,Yugarajah Asokumaran,Robert John Walsh,Rachel Su Jen Wong,Zhi Yao Chan,Ross A. Soo,Raghav Sundar,Wei Peng Yong

Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.

2020

Jia Li Low
Kenneth Sooi
Yiqing Huang
Gloria Hj Chan
Yvonne L.E. Ang
Wan Qin Chong
Hon-Lyn Tan
Natalie Ngoi
Joan Choo
Matilda Lee
Vaishnavi Muthu
Yugarajah Asokumaran
Robert John Walsh
Rachel Su Jen Wong
Zhi Yao Chan
Ross A. Soo
Raghav Sundar
Wei Peng Yong

e19385Background: Pembrolizumab has dramatically improved the survival of patients with non-small cell lung cancer (NSCLC) and is considered the standard of care for first line treatment of NSCLC w...

Keywords:

Oncology
low dose
Lung cancer
non small cell
Internal medicine
Pathology
Pembrolizumab
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations